Oxford Vaccine Demonstrates 70% Protection Against SARS-CoV-2

The Sars-CoV-2 vaccine developed by the University of Oxford demonstrated average efficacy of 70.4%, according to results of clinical trials.

The interim analysis of phase 2/3 trials in the UK and Brazil found efficacy of 62% following two full doses given at least one month apart.

However, vaccine efficacy was 90% when ChAdOx1 nCoV-19, also known as AZD1222, was given to a subset of participants as a half dose, followed by a full dose at least one month later.

No hospitalisations or severe cases of the disease were reported in participants who received the vaccine, Oxford’s partner AstraZeneca said in a press release this morning.

The data also suggested a half dose and full dose regime could help to prevent transmission of the virus, according to a press release from the University of Oxford.

Sarah Gilbert, professor of vaccinology at Oxford, said: “The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by SARS-CoV-2.”

The announcement follows promising interim data from Pfizer-BioNTech and Moderna, which recently demonstrated protection of around 95% against developing COVID-19 with their messenger RNA (mRNA) vaccines

However, the Oxford vaccine is cheaper to produce, and unlike the other vaccines that require a demanding cold chain storage, can be kept at standard refrigerator temperatures of between 2C and 8C.

‘Exciting’ News

Prof Andrew Pollard, director of the Oxford Vaccine Group, said: “These findings show that we have an effective vaccine that will save many lives.

Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.”

Asked why giving a half dose followed by a full dose appeared to be more effective, Prof Pollard told a briefing hosted by the Science Media Centre: “We think that by giving a smaller first dose that we’re priming the immune system differently, we’re setting it up better to respond.”

He added: “What we don’t know at this moment is whether that difference is in the quality or the quantity of the immune response, and that’s something we are doing to be digging into.”

Pascal Soriot, AstraZeneca’s chief executive Officer, said using a halved first dose and a standard second dose would mean “we can vaccinate more people, faster”.

AstraZeneca Prepares to Seek Regulatory Approval

The company said it would immediately prepare regulatory submission of the data to authorities around the world.

Trial results will be submitted to a scientific journal for peer review.

The pooled analysis included data from the COV002 Phase 2/3 trial in the UK and COV003 phase 3 trial in Brazil, and involved more than 23,000 participants.

Dr Zania Stamataki, viral immunologist at the University of Birmingham, commented: ” People will be tempted to compare efficacy between the different vaccines but we must remember that these are early data designed to achieve approval. Efficacy is not the same as effectiveness and the early numbers

Read more

LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect

UPPSALA, SWEDEN – LIDDS AB (publ) announces that intratumoral injection of NZ-TLR9, NanoZolid (NZ) formulation of a Toll-Like Receptor 9 (TLR9), results in strong antitumoral efficacy combined with prominent antitumoral immune responses in mouse tumor models. NZ-TLR9 forms an intratumoral depot which releases the TLR9 agonist for least 6 weeks and thus minimizes the need for repeated injections. Furthermore, we have identified both intratumoral- and plasma biomarkers needed to measure the activity of NZ-TLR9 in clinical trials.

LIDDS has completed a preclinical data package using a TLR9 agonist formulated with NanoZolid®(NZ-TLR9) showing that a single NZ-TLR9 injection is reducing tumor growth and improves the survival of mice, with increase of intratumoral cytotoxic T- cells and activated dendritic cells. The TLR9 agonist is released during at least 6 weeks with equal in vivo efficacy which minimizes the need for repeated injections, which are needed when using standard formulated TLR9 agonists. In addition, the study also identified plasma biomarkers which are suitable to measure the biological activity of NZ-TLR9 in coming clinical trial.

-I’m really happy to see our convincing preclinical data package with NanoZolid formulated TLR9, especially the six weeks of controlled release with strong anti-tumor effect. The results indicate that NanoZolid technology®, with controlled and sustained drug release, can be used to treat deep lying cancer tumors. These tumors are not suitable to be treated with standard TLR9 due to the necessity of weekly injections. The planning for a Phase I study treating solid tumors with intratumoral NZ-TLR9 is ongoing and we plan to start the study towards the second half of 2021, commented Monica Wallter, CEO of LIDDS.

About TLRs and TLR9
Toll-like receptors (TLRs) are key targets in the search for new treatments against cancer. TLRs are expressed on various immune cells, including dendritic cells, and upon activation they initiate the body’s immune response. TLR9 activation leads to an immunologically active tumor environment with recruitment of the cytotoxic T cells which are necessary for an antitumor response in immunotherapy. Thus, TLR9 agonists can convert immunologically “cold” tumors to immunologically “hot” tumors. The most promising target cancers for the TLR9 project are head and neck cancer, prostate cancer, sarcomas and lymphomas. These malignancies are diagnosed in around 2 million patients each year. The market for TLR agonists is expected to be worth hundreds of millions of dollars over the coming years.  

For additional information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, [email protected]

This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above on October 26, 2020 at 08:30 CET.

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid

Read more